TY - JOUR AU - Zahoor, H. AU - Rini, B. I. PY - 2016 DA - 2016// TI - Emerging growth factor receptor antagonists for the treatment of renal cell carcinoma JO - Expert Opin Emerg Drugs VL - 21 UR - https://doi.org/10.1080/14728214.2016.1244263 DO - 10.1080/14728214.2016.1244263 ID - Zahoor2016 ER - TY - JOUR AU - Choueiri, T. K. PY - 2011 DA - 2011// TI - VEGF inhibitors in metastatic renal cell carcinoma: current therapies and future perspective JO - Curr Clin Pharmacol VL - 6 UR - https://doi.org/10.2174/157488411797189424 DO - 10.2174/157488411797189424 ID - Choueiri2011 ER - TY - JOUR AU - Albiges, L. AU - Salem, M. AU - Rini, B. AU - Escudier, B. PY - 2011 DA - 2011// TI - Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma JO - Hematol Oncol Clin North Am VL - 25 UR - https://doi.org/10.1016/j.hoc.2011.04.006 DO - 10.1016/j.hoc.2011.04.006 ID - Albiges2011 ER - TY - JOUR AU - Fyfe, G. AU - Fisher, R. I. AU - Rosenberg, S. A. AU - Sznol, M. AU - Parkinson, D. R. AU - Louie, A. C. PY - 1995 DA - 1995// TI - Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. Journal of clinical oncology : official journal of the JO - Proc Am Soc Clin Oncol VL - 13 UR - https://doi.org/10.1200/JCO.1995.13.3.688 DO - 10.1200/JCO.1995.13.3.688 ID - Fyfe1995 ER - TY - JOUR AU - Carlo, M. I. AU - Voss, M. H. AU - Motzer, R. J. PY - 2016 DA - 2016// TI - Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma JO - Nature reviews Urol VL - 13 UR - https://doi.org/10.1038/nrurol.2016.103 DO - 10.1038/nrurol.2016.103 ID - Carlo2016 ER - TY - JOUR AU - Motzer, R. J. AU - Escudier, B. AU - McDermott, D. F. AU - George, S. AU - Hammers, H. J. AU - Srinivas, S. PY - 2015 DA - 2015// TI - Nivolumab versus Everolimus in advanced renal-cell carcinoma JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1510665 DO - 10.1056/NEJMoa1510665 ID - Motzer2015 ER - TY - JOUR AU - Heng, D. Y. AU - Xie, W. AU - Regan, M. M. AU - Warren, M. A. AU - Golshayan, A. R. AU - Sahi, C. PY - 2009 DA - 2009// TI - Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. Journal of clinical oncology : official journal of the JO - Proc Am Soc Clin Oncol VL - 27 UR - https://doi.org/10.1200/JCO.2008.21.4809 DO - 10.1200/JCO.2008.21.4809 ID - Heng2009 ER - TY - JOUR AU - Motzer, R. J. AU - Tannir, N. M. AU - McDermott, D. F. AU - Aren Frontera, O. AU - Melichar, B. AU - Choueiri, T. K. PY - 2018 DA - 2018// TI - Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma JO - N Engl J Med VL - 378 UR - https://doi.org/10.1056/NEJMoa1712126 DO - 10.1056/NEJMoa1712126 ID - Motzer2018 ER - TY - JOUR AU - Inai, T. AU - Mancuso, M. AU - Hashizume, H. AU - Baffert, F. AU - Haskell, A. AU - Baluk, P. PY - 2004 DA - 2004// TI - Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts JO - Am J Pathol VL - 165 UR - https://doi.org/10.1016/S0002-9440(10)63273-7 DO - 10.1016/S0002-9440(10)63273-7 ID - Inai2004 ER - TY - JOUR AU - David, F. AU - J-LL, M. D. AU - Szczylik, C. AU - Donskov, F. AU - Malik, J. AU - Alekseev, B. Y. AU - Larkin, J. M. G. AU - Matveev, V. B. AU - Gafanov, R. A. AU - Tomczak, P. AU - Tykodi, S. S. AU - Geertsen, P. F. AU - Wiechno, P. J. AU - Shin, S. J. AU - Pouliot, F. AU - Gordoa, T. A. AU - Li, W. AU - Perini, R. F. AU - Schloss, C. AU - Atkins, M. B. PY - 2018 DA - 2018// TI - Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (accRCC): results from cohort a of KEYNOTE-427 JO - J Clin Oncol VL - 36 ID - David2018 ER - TY - JOUR AU - Massard, C. AU - Zonierek, J. AU - Gross-Goupil, M. AU - Fizazi, K. AU - Szczylik, C. AU - Escudier, B. PY - 2010 DA - 2010// TI - Incidence of brain metastases in renal cell carcinoma treated with sorafenib JO - Ann Oncol VL - 21 UR - https://doi.org/10.1093/annonc/mdp411 DO - 10.1093/annonc/mdp411 ID - Massard2010 ER - TY - JOUR AU - Muldoon, L. L. AU - Soussain, C. AU - Jahnke, K. AU - Johanson, C. AU - Siegal, T. AU - Smith, Q. R. PY - 2007 DA - 2007// TI - Chemotherapy delivery issues in central nervous system malignancy: a reality check JO - J Clin Oncol VL - 25 UR - https://doi.org/10.1200/JCO.2006.09.9861 DO - 10.1200/JCO.2006.09.9861 ID - Muldoon2007 ER - TY - JOUR AU - Kim, E. S. AU - Bruinooge, S. S. AU - Roberts, S. AU - Ison, G. AU - Lin, N. U. AU - Gore, L. PY - 2017 DA - 2017// TI - Broadening eligibility criteria to make clinical trials more representative: American Society of Clinical Oncology and friends of Cancer research joint research statement JO - J Clin Oncol VL - 35 UR - https://doi.org/10.1200/JCO.2017.73.7916 DO - 10.1200/JCO.2017.73.7916 ID - Kim2017 ER - TY - JOUR AU - Laurence Albiges, S. N. AU - Dalban, C. AU - Gravis, G. AU - Chevreau, C. AU - Oudard, S. AU - Laguerre, B. AU - Barthelemy, P. AU - Borchiellini, D. AU - Gross-Goupil, M. AU - Geoffrois, L. AU - Brihoum, M. AU - Escudier, B. PY - 2018 DA - 2018// TI - Safety and efficacy of nivolumab in metastatic renal cell carcinoma (mRCC): results from the NIVOREN GETUG-AFU 26 study JO - J Clin Oncol VL - 36 UR - https://doi.org/10.1200/JCO.2018.36.6_suppl.577 DO - 10.1200/JCO.2018.36.6_suppl.577 ID - Laurence Albiges2018 ER - TY - JOUR AU - Topalian, S. L. AU - Hodi, F. S. AU - Brahmer, J. R. AU - Gettinger, S. N. AU - Smith, D. C. AU - McDermott, D. F. PY - 2012 DA - 2012// TI - Safety, activity, and immune correlates of anti-PD-1 antibody in cancer JO - N Engl J Med VL - 366 UR - https://doi.org/10.1056/NEJMoa1200690 DO - 10.1056/NEJMoa1200690 ID - Topalian2012 ER - TY - JOUR AU - Snyder, A. AU - Makarov, V. AU - Merghoub, T. AU - Yuan, J. AU - Zaretsky, J. M. AU - Desrichard, A. PY - 2014 DA - 2014// TI - Genetic basis for clinical response to CTLA-4 blockade in melanoma JO - N Engl J Med VL - 371 UR - https://doi.org/10.1056/NEJMoa1406498 DO - 10.1056/NEJMoa1406498 ID - Snyder2014 ER - TY - JOUR AU - McDermott, D. F. AU - Huseni, M. A. AU - Atkins, M. B. AU - Motzer, R. J. AU - Rini, B. I. AU - Escudier, B. PY - 2018 DA - 2018// TI - Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma JO - Nat Med VL - 24 UR - https://doi.org/10.1038/s41591-018-0053-3 DO - 10.1038/s41591-018-0053-3 ID - McDermott2018 ER - TY - JOUR AU - Tumeh, P. C. AU - Harview, C. L. AU - Yearley, J. H. AU - Shintaku, I. P. AU - Taylor, E. J. AU - Robert, L. PY - 2014 DA - 2014// TI - PD-1 blockade induces responses by inhibiting adaptive immune resistance JO - Nature VL - 515 UR - https://doi.org/10.1038/nature13954 DO - 10.1038/nature13954 ID - Tumeh2014 ER - TY - JOUR AU - Nishino, M. AU - Ramaiya, N. H. AU - Hatabu, H. AU - Hodi, F. S. PY - 2017 DA - 2017// TI - Monitoring immune-checkpoint blockade: response evaluation and biomarker development JO - Nat Rev Clin Oncol VL - 14 UR - https://doi.org/10.1038/nrclinonc.2017.88 DO - 10.1038/nrclinonc.2017.88 ID - Nishino2017 ER - TY - JOUR AU - Martens, A. AU - Wistuba-Hamprecht, K. AU - Geukes Foppen, M. AU - Yuan, J. AU - Postow, M. A. AU - Wong, P. PY - 2016 DA - 2016// TI - Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with Ipilimumab JO - Clin Cancer Res VL - 22 UR - https://doi.org/10.1158/1078-0432.CCR-15-2412 DO - 10.1158/1078-0432.CCR-15-2412 ID - Martens2016 ER - TY - JOUR AU - Delyon, J. AU - Mateus, C. AU - Lefeuvre, D. AU - Lanoy, E. AU - Zitvogel, L. AU - Chaput, N. PY - 2013 DA - 2013// TI - Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival JO - Ann Oncol VL - 24 UR - https://doi.org/10.1093/annonc/mdt027 DO - 10.1093/annonc/mdt027 ID - Delyon2013 ER - TY - JOUR AU - Ku, G. Y. AU - Yuan, J. AU - Page, D. B. AU - Schroeder, S. E. AU - Panageas, K. S. AU - Carvajal, R. D. PY - 2010 DA - 2010// TI - Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival JO - Cancer VL - 116 UR - https://doi.org/10.1002/cncr.24951 DO - 10.1002/cncr.24951 ID - Ku2010 ER - TY - JOUR AU - Boussiotis, V. A. PY - 2016 DA - 2016// TI - Molecular and Biochemical aspects of the PD-1 checkpoint pathway JO - N Engl J Med VL - 375 UR - https://doi.org/10.1056/NEJMra1514296 DO - 10.1056/NEJMra1514296 ID - Boussiotis2016 ER - TY - JOUR AU - Dumitru, C. A. AU - Moses, K. AU - Trellakis, S. AU - Lang, S. AU - Brandau, S. PY - 2012 DA - 2012// TI - Neutrophils and granulocytic myeloid-derived suppressor cells: immunophenotyping, cell biology and clinical relevance in human oncology JO - Cancer Immunol Immunother VL - 61 UR - https://doi.org/10.1007/s00262-012-1294-5 DO - 10.1007/s00262-012-1294-5 ID - Dumitru2012 ER - TY - JOUR AU - Chen, Y. AU - Yan, H. AU - Wang, Y. AU - Shi, Y. AU - Dai, G. PY - 2017 DA - 2017// TI - Significance of baseline and change in neutrophil-to-lymphocyte ratio in predicting prognosis: a retrospective analysis in advanced pancreatic ductal adenocarcinoma JO - Sci Rep VL - 7 UR - https://doi.org/10.1038/s41598-017-00859-5 DO - 10.1038/s41598-017-00859-5 ID - Chen2017 ER - TY - JOUR AU - Pillay, J. AU - Kamp, V. M. AU - van Hoffen, E. AU - Visser, T. AU - Tak, T. AU - Lammers, J. W. PY - 2012 DA - 2012// TI - A subset of neutrophils in human systemic inflammation inhibits T cell responses through mac-1 JO - J Clin Invest VL - 122 UR - https://doi.org/10.1172/JCI57990 DO - 10.1172/JCI57990 ID - Pillay2012 ER - TY - JOUR AU - Kobayashi, M. AU - Kubo, T. AU - Komatsu, K. AU - Fujisaki, A. AU - Terauchi, F. AU - Natsui, S. PY - 2013 DA - 2013// TI - Changes in peripheral blood immune cells: their prognostic significance in metastatic renal cell carcinoma patients treated with molecular targeted therapy JO - Med Oncol VL - 30 UR - https://doi.org/10.1007/s12032-013-0556-1 DO - 10.1007/s12032-013-0556-1 ID - Kobayashi2013 ER - TY - JOUR AU - Kumar, R. AU - Geuna, E. AU - Michalarea, V. AU - Guardascione, M. AU - Naumann, U. AU - Lorente, D. PY - 2015 DA - 2015// TI - The neutrophil-lymphocyte ratio and its utilisation for the management of cancer patients in early clinical trials JO - Br J Cancer VL - 112 UR - https://doi.org/10.1038/bjc.2015.67 DO - 10.1038/bjc.2015.67 ID - Kumar2015 ER - TY - JOUR AU - Templeton, A. J. AU - Knox, J. J. AU - Lin, X. AU - Simantov, R. AU - Xie, W. AU - Lawrence, N. PY - 2016 DA - 2016// TI - Change in neutrophil-to-lymphocyte ratio in response to targeted therapy for metastatic renal cell carcinoma as a prognosticator and biomarker of efficacy JO - Eur Urol VL - 70 UR - https://doi.org/10.1016/j.eururo.2016.02.033 DO - 10.1016/j.eururo.2016.02.033 ID - Templeton2016 ER - TY - JOUR AU - Lalani, A. A. AU - Xie, W. AU - Martini, D. J. AU - Steinharter, J. A. AU - Norton, C. K. AU - Krajewski, K. M. PY - 2018 DA - 2018// TI - Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma JO - J Immunother Cancer VL - 6 UR - https://doi.org/10.1186/s40425-018-0315-0 DO - 10.1186/s40425-018-0315-0 ID - Lalani2018 ER - TY - JOUR AU - Tsuyuki, S. AU - Tsuyuki, J. AU - Einsle, K. AU - Kopf, M. AU - Coyle, A. J. PY - 1997 DA - 1997// TI - Costimulation through B7-2 (CD86) is required for the induction of a lung mucosal T helper cell 2 (TH2) immune response and altered airway responsiveness JO - J Exp Med VL - 185 UR - https://doi.org/10.1084/jem.185.9.1671 DO - 10.1084/jem.185.9.1671 ID - Tsuyuki1997 ER - TY - JOUR AU - Alenmyr, L. AU - Matheu, V. AU - Uller, L. AU - Greiff, L. AU - Malm-Erjefalt, M. AU - Ljunggren, H. G. PY - 2005 DA - 2005// TI - Blockade of CTLA-4 promotes airway inflammation in naive mice exposed to aerosolized allergen but fails to prevent inhalation tolerance JO - Scand J Immunol VL - 62 UR - https://doi.org/10.1111/j.1365-3083.2005.01682.x DO - 10.1111/j.1365-3083.2005.01682.x ID - Alenmyr2005 ER - TY - STD TI - Lydia Gaba IV, Estela Pineda, Aranzazu Fernandez, Francisco Aya, Aleix Prat, Ana M Arance. Changes in blood eosinophilia during anti-PD1 therapy as a predictor of long term disease control in metastatic melanoma. J Clin Oncol 33, no 15_suppl 9069–9069. 2015. ID - ref33 ER -